Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mus musculus strain:Tg(ACTB-cre)2Mrt TgTn(sb-T2/Onc3)12740Njen Gt(ROSA)26Sortm2(sb11)Njen | breed:Lab stock

ABSTRACT: Mus musculus strain:Tg(ACTB-cre)2Mrt TgTn(sb-T2/Onc3)12740Njen Gt(ROSA)26Sortm2(sb11)Njen | breed:Lab stock Raw sequence reads

PROVIDER: PRJNA580460 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR10585203.fastq.gz	Fastqsanger.gz
	SRR10585204.fastq.gz	Fastqsanger.gz
	SRR10585205.fastq.gz	Fastqsanger.gz
	SRR10585206.fastq.gz	Fastqsanger.gz
	SRR10585207.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 7

Similar Datasets

Mus musculus strain:Tg(Ipf1-cre)6Tuv Kras^tm4Tyj TgTn(sb-T2/Onc3)12740Njen Gt(ROSA)26Sortm2(sb11)Njen

Project description:Mus musculus strain:Tg(Ipf1-cre)6Tuv Kras^tm4Tyj TgTn(sb-T2/Onc3)12740Njen Gt(ROSA)26Sortm2(sb11)Njen Raw sequence reads

| PRJNA664797 | ENA

Mus musculus strain:Tg(ACTB-cre)2Mrt TgTn(sb-T2/Onc3)12740Njen Gt(ROSA)26Sortm2(sb11)Njen | breed:Lab stock

Project description:Mus musculus strain:Tg(ACTB-cre)2Mrt TgTn(sb-T2/Onc3)12740Njen Gt(ROSA)26Sortm2(sb11)Njen | breed:Lab stock Transcriptome or Gene expression

| PRJNA580462 | ENA

Mus musculus strain:Tg(Ipf1-cre)6Tuv Kras^tm4Tyj TgTn(sb-T2/Onc3)12740Njen Gt(ROSA)26Sortm2(sb11)Njen | isolate:SingleCells

Project description:Mus musculus strain:Tg(Ipf1-cre)6Tuv Kras^tm4Tyj TgTn(sb-T2/Onc3)12740Njen Gt(ROSA)26Sortm2(sb11)Njen | isolate:SingleCells Raw sequence reads

| PRJNA664792 | ENA

Mus musculus strain:Tg(ACTB-cre)2Mrt TgTn(sb-T2/Onc2)6113Njen Gt(ROSA)26Sortm2(sb11)Njen

Project description:Mus musculus strain:Tg(ACTB-cre)2Mrt TgTn(sb-T2/Onc2)6113Njen Gt(ROSA)26Sortm2(sb11)Njen Genome sequencing and assembly

| PRJNA285079 | ENA

Massilia horti strain:ONC3

Project description:Massilia horti ONC3 Genome sequencing and assembly

| PRJNA529408 | ENA

Suillus bovinus isolate:SB11

Project description:Suillus bovinus isolate:SB11 Genome sequencing

| PRJNA1065574 | ENA

Mus musculus strain:Tg(ACTB-cre)2Mrt TgTn(sb-T2/Onc2)6113Njen Gt(ROSA)26Sortm2(sb11)Njen

Project description:Mus musculus Sleeping Beauty capture-enrichment genome sequencing

| PRJNA325944 | ENA

Draft Genome Sequence of Massilia sp. Strain ONC3, a Novel Bacterial Species of the Oxalobacteraceae Family Isolated from Garden Soil.

Project description:From garden soil, we isolated and sequenced Massilia sp. strain ONC3, a new member of the Oxalobacteraceae within the Massilia genus. Sequence analysis showed an assembled genome size of 5,622,601 bp, with a predicted total of 5,104 protein-coding sequences, 3,194 functionally assigned genes, 2 rRNA operons, and 56 tRNAs.

| S-EPMC6687914 | biostudies-literature

Pseudomonas psychrotolerans strain:SB11

Project description:Pseudomonas psychrotolerans Genome Sequencing

| PRJNA278435 | ENA

Project description:Background/aimsTo provide longer-term data on efficacy, safety, immunogenicity and pharmacokinetics (PK) of ranibizumab biosimilar SB11 compared with the reference ranibizumab (RBZ) in patients with neovascular age-related macular degeneration (nAMD).MethodsSetting: Multicentre. Design: Randomised, double-masked, parallel-group, phase III equivalence study. Patient population: ≥50 years old participants with nAMD (n=705), one 'study eye'.Intervention1:1 randomisation to monthly intravitreal injection of 0.5 mg SB11 or RBZ. Main outcome measures: Visual efficacy endpoints, safety, immunogenicity and PK up to 52 weeks.ResultsBaseline and disease characteristics were comparable between treatment groups. Of 705 randomised participants (SB11: n=351; RBZ: n=354), 634 participants (89.9%; SB11: n=307; RBZ: n=327) completed the study until week 52. Previously reported equivalence in primary efficacy remained stable up to week 52 and were comparable between SB11 and RBZ. The adjusted treatment difference between SB11 and RBZ in full analysis set at week 52 of change from baseline in best-corrected visual acuity was -0.6 letters (90% CI -2.1 to 0.9) and of change from baseline in central subfield thickness was -14.9 µm (95% CI -25.3 to -4.5). The incidence of ocular treatment-emergent adverse events (TEAEs) (SB11: 32.0% vs RBZ: 29.7%) and serious ocular TEAE (SB11: 2.9% vs RBZ: 2.3%) appeared comparable between treatment groups, and no new safety concerns were observed. The PK and immunogenicity profiles were comparable, with a 4.2% and 5.5% cumulative incidence of antidrug antibodies up to week 52 for SB11 and RBZ, respectively.ConclusionsLonger-term results of this study further support the biosimilarity established between SB11 and RBZ.

| S-EPMC9985746 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data